logoTry Persana

Trestle Biotherapeutics - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Trestle Biotherapeutics including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Trestle Biotherapeutics company logo

Bioengineered Therapies for Kidney Disease

Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease.

HeadquartersSan Diego, United States
Team size1-10
FoundedNA

What is Trestle Biotherapeutics? - Company Overview & Details

Trestle Biotherapeutics is Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease., the company is headquartered in San Diego, United States.

Who Founded Trestle Biotherapeutics?

Trestle Biotherapeutics was founded by Ben Shepherd, Ph.D., Alice Chen, Ph.D..

Who are the Key Executives at Trestle Biotherapeutics? - Leadership Team

Trestle Biotherapeutics is led by experienced executives in key positions:

Chief Executive Officer (CEO) of Trestle Biotherapeutics

Ben ShepherdCEO

About Ben Shepherd - CEO of Trestle Biotherapeutics

Ben Shepherd serves as the Chief Executive Officer of Trestle Biotherapeutics, leading the company's strategic vision and operations. Connect with them on LinkedIn for professional insights.

Trestle Biotherapeutics Company Details & Key Information

Where is Trestle Biotherapeutics located?

Trestle Biotherapeutics is headquartered in San Diego, United States.

How many employees does Trestle Biotherapeutics have?

Trestle Biotherapeutics has 1-10 employees.

Trestle Biotherapeutics Official Website

How much funding has Trestle Biotherapeutics raised?

Trestle Biotherapeutics has raised $1 Million across 3 funding rounds. The most recent funding was completed on 2023-07-12.

Funding Overview

Trestle Biotherapeutics has raised a total of $1 million through grants to support its research and development efforts.

$1 Million
Total Funding Raised
3
Funding Rounds
2023-07-12
Latest Round

Trestle Biotherapeutics Funding History

Grant
2023-07-12
$1 Million

Who are the key investors in Trestle Biotherapeutics?

Trestle Biotherapeutics is backed by 1 key investors including KidneyX Innovation Accelerator. These investors focus on Kidney health, Biotechnological innovations sectors.

Trestle Biotherapeutics Investor Overview

1
Key Investors
2
Focus Areas
0
Notable Investments

Complete List of Trestle Biotherapeutics Investors

KidneyX Innovation Accelerator

Investment Focus
Kidney health
Biotechnological innovations

What sectors do Trestle Biotherapeutics investors focus on?

The investors backing Trestle Biotherapeutics primarily focus on Kidney health, Biotechnological innovations sectors.

Kidney health
Biotechnological innovations

Featured Investor: KidneyX Innovation Accelerator

KidneyX Innovation Accelerator

Notable Investments:

What are Trestle Biotherapeutics's future plans?

Trestle Biotherapeutics Trestle Biotherapeutics aims to expand its research and development efforts and enhance collaborations with academic partners.

Trestle Biotherapeutics Strategic Outlook

Strategic Focus
Defined
0
Key Challenges
0
Growth Opportunities

What are the latest news about Trestle Biotherapeutics?

Trestle Biotherapeutics has 2 recent news updates covering key business developments and market activities.

Trestle Biotherapeutics News Overview

2
Recent Articles
Active
Media Coverage
2022-04-04
Latest Update

What is Trestle Biotherapeutics in the news for?

Trestle Biotherapeutics is currently featured in news for Trestlebio recognized as “Cool Company on Apr 5th '22. and other significant business developments.

Recent News Articles About Trestle Biotherapeutics

Article 1
2022-04-04

Trestlebio recognized as “Cool Company on Apr 5th '22.

Trestle Biotherapeutics announced today that it has been selected as a “Cool Company” by Connect San Diego.

trestlebio.com
Read News
Article 2
2022-02-08

Trestlebio partnered with Harvard Business School Publishing Corporation on Feb 8th '22.

Trestle Biotherapeutics announced a license agreement with Harvard University to develop 3D biofabricated tissues.

biospace.com
Read News

Trestle Biotherapeutics FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Trestle Biotherapeutics including information about founders, CEO, funding history, investors, headquarters location, and company details. 15 frequently asked questions covering key information about the company.

Trestle Biotherapeutics Questions & Answers - Company Information

Q1

What is Trestle Biotherapeutics?

Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease.

Q2

Who founded Trestle Biotherapeutics?

Trestle Biotherapeutics was founded by Ben Shepherd, Ph.D., Alice Chen, Ph.D..

Q3

Who is the CEO of Trestle Biotherapeutics?

The CEO of Trestle Biotherapeutics is Ben Shepherd. You can find more information about them on their LinkedIn profile.

Q4

How much funding has Trestle Biotherapeutics raised?

Trestle Biotherapeutics has raised a total of $$1 Million across 3 funding rounds. The most recent funding was completed on 2023-07-12.

Q5

Who are the investors in Trestle Biotherapeutics?

Trestle Biotherapeutics's key investors include KidneyX Innovation Accelerator.

Q6

Where is Trestle Biotherapeutics headquartered?

Trestle Biotherapeutics is headquartered in San Diego, United States.

Q7

How many employees does Trestle Biotherapeutics have?

Trestle Biotherapeutics has 1-10 employees.

Q8

What is Trestle Biotherapeutics's official website?

You can visit Trestle Biotherapeutics's official website at http://www.trestlebio.com.

Q9

What was Trestle Biotherapeutics's latest funding round?

Trestle Biotherapeutics's latest funding round was a Grant round of $$1 Million completed on 2023-07-12.

Q10

Who is founder?

Ben Shepherd

Q11

What does the company do?

Trestle Biotherapeutics develops bioengineered therapies for patients living with end stage renal disease.

Q12

How much funding?

$1 Million

Q13

Latest funding date?

2023-07-12

Q14

Who are the investors?

KidneyX Innovation Accelerator

Q15

Latest news?

Trestle Biotherapeutics announced today that it has been selected as a “Cool Company” by Connect San Diego. Trestle Biotherapeutics announced a license agreement with Harvard University to develop 3D biofabricated tissues.

More Information About Trestle Biotherapeutics

For additional details about Trestle Biotherapeutics, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.